Raia Drogasil (OTCMKTS:RADLY – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported $0.05 EPS for the quarter, hitting the consensus estimate of $0.05, Zacks reports. Raia Drogasil had a net margin of 2.99% and a return on equity of 20.12%.
Raia Drogasil Stock Down 5.4%
Shares of OTCMKTS:RADLY traded down $0.15 on Tuesday, hitting $2.70. 25,105 shares of the company’s stock were exchanged, compared to its average volume of 83,417. The firm’s 50-day moving average is $3.72 and its 200 day moving average is $4.07. The company has a market capitalization of $3.55 billion and a PE ratio of 17.98. Raia Drogasil has a 1-year low of $2.63 and a 1-year high of $5.34. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.58 and a current ratio of 1.41.
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group upgraded shares of Raia Drogasil to a “buy” rating and set a $5.20 price objective on the stock in a report on Sunday, October 18th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $5.20.
Read Our Latest Stock Report on Raia Drogasil
Raia Drogasil Company Profile
Raia Drogasil, now operating under the name RD Saúde, is a Brazilian healthcare and pharmacy retail company. It operates a network of pharmacies offering prescription medicines, over-the-counter drugs, vitamins, personal care products, beauty items and other health-related merchandise.
The company also provides digital purchasing and delivery services through its online channels, supporting customers with prescription fulfillment, health products and related services. Its operations include pharmacy-based healthcare initiatives designed to complement its retail business and improve access to everyday healthcare.
RD Saúde was created in 2011 through the merger of Drogasil and Droga Raia, two established Brazilian pharmacy chains.
Featured Stories
- Five stocks we like better than Raia Drogasil
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
